Expert Interviews

Panelists discuss the progress of the BRIDGET trial and its potential impact on HER2-positive breast cancer patients, focusing on the anticipated data and its implications for treatment strategies in this population.

Panelists discuss how ongoing trials may reshape the treatment landscape for HER2-altered NSCLC, particularly regarding the roles of ADCs and TKIs in managing both HER2-mutated and HER2-overexpressing NSCLC.

Panelists discuss a brief overview of recent data on combination systemic therapies for the treatment of advanced HER2+ breast cancer, including studies such as DESTINY-Breast03, DEBBRAH, HER2CLIMB-02, and EMILIA, and they analyze which patient populations may benefit most from each therapy option based on the available data.

An intravenous infusion administered prior to surgery enables treatment to occur in a normal time frame without the need for additional procedural time.

Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.

Panelists discuss how health care providers engage in vital conversations with patients about CAR T therapy, focusing on comprehensive education, emotional support, and clear communication about the treatment journey ahead.

Panelists discuss how the symptoms of a patient with multiple myeloma led to their initial diagnosis and the progression of various treatments they underwent before becoming a candidate for CAR T therapy.

Panelists discuss how the patient’s journey with multiple myeloma begins with an initial diagnosis followed by first-line treatments and how this informs the decision to consider chimeric antigen receptor T-cell therapy as a subsequent option in their treatment path.

In an era where medical records are digitalized, artificial intelligence has the potential to identify patterns that can locate at-risk patients with pancreatic cancer.

The relatively inexpensive nature of liquid biopsy may allow for more frequent screening among individuals who are at risk of developing pancreatic cancer.

There are certain markers that can point to a greater risk of pancreatic cancer like BRCA1/2, and diabetes, according to Brian M. Wolpin, MD.

Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.

The pancreatic cancer field may not be far from seeing the use of non-invasive blood tests in pancreatic cancer, said Ajay Goel, PhD, AGAF.

Dr Nadeem discusses his approach to sequencing bispecifics vs chimeric antigen receptor T-cell therapies, including B-cell maturation antigen (BCMA) and non-BCMA bispecifics, and the factors he considers, followed by key takeaways from a recent meeting on bispecifics in relapsed/refractory multiple myeloma, focusing on dosing, adverse event management, and clinical pearls for oncologists.

Dr Nadeem discusses his case details and shares his initial thoughts. He then reviews the current treatment landscape for relapsed/refractory multiple myeloma, including his experience with bispecifics in practice and his challenges in using them.

Panelist discusses the current acceleration of new therapies for multiple myeloma. In the future, oncologists will be able to use CAR T and bispecific therapies more efficiently, and they will also have new tools including new CAR T therapies and bispecifics that will require less manufacturing time, have fewer AEs, and be more effective regarding the targeted disease.

Panelist discusses how every drug oncologists use comes with adverse events (AEs), and with bispecifics they are seeing a similar AE profile to that seen in CAR T-cell therapy. There are 3 major AEs: cytokine release syndrome, neurological toxicity, and infections. To manage AEs, oncologists are now monitoring patients more intensely as well as engaging with the patient’s family to provide updates on the status of the patient.

Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.

Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy in early relapsed multiple myeloma can provide deep and durable responses for eligible patients, though patient selection, timing of referral, manufacturing logistics, and management of adverse effects remain important considerations in optimizing outcomes.

Panelist discusses how bispecifics have had a major impact in relapsed/refractory multiple myeloma (R/R MM) because they provide a different way of attacking myeloma, allow oncologists an opportunity to care for patients who cannot have CAR T therapy, and allow oncologist to treat patients who have had an aggressive relapse. The panelist further discusses the importance of bispecifics dosing specifically to maintain a response with the drug but also to prevent the risk of patient infection.